Wall Street Zen Upgrades Edwards Lifesciences (NYSE:EW) to Buy

Posted by Geri Gentry on Oct 19th, 2026

Edwards Lifesciences (NYSE:EW – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also commented on EW. Citigroup restated a “buy” rating on shares of Edwards Lifesciences in a research note on Monday, October 5th. Truist Financial boosted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Thursday. Mizuho increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Evercore restated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $100.27.

View Our Latest Stock Report on Edwards Lifesciences

Edwards Lifesciences Stock Down 0.1%

Edwards Lifesciences stock opened at $86.52 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences has a one year low of $72.67 and a one year high of $96.29. The company has a 50-day simple moving average of $88.44 and a 200-day simple moving average of $86.38. The firm has a market capitalization of $49.82 billion, a P/E ratio of 49.72, a P/E/G ratio of 2.27 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts expect that Edwards Lifesciences will post 3.00 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,045 shares of company stock worth $451,596 in the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter valued at $26,000. Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $26,000. Finally, GK Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $26,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.